Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes

Diabetes Care

Volumn 26, Issue 9, 2003, Pages 2628-2631

  Roguin, Ariel ^a   Koch, Werner ^b   Kastrati, Adnan ^b   Aronson, Doron ^a   Schomig, Albert ^b   Levy, Andrew P ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HAPTOGLOBIN; INSULIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DEATH; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; EVALUATION; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE LOCUS; GENOTYPE; HEART INFARCTION; HP1 1 GENE; HP2 1 GENE; HP2 2 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; RESTENOSIS; TREATMENT PLANNING;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CORONARY RESTENOSIS; DIABETIC ANGIOPATHIES; FEMALE; GENOTYPE; HAPTOGLOBINS; HUMANS; MALE; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0042536434     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.9.2628     Document Type: Article

References (27)

1. Howard BV, Magee MF: Diabetes and cardiovascular disease. Curr Atheroscler Rep 2:476-481, 2000
2. U.K. Prospective Diabetes Study Group: Ethnicity and cardiovascular disease: the incidence of myocardial infarction in white, south Asian and afro-Caribbean patients with type 2 diabetes. Diabetes Care 21:1271-1277, 1998
3. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA, Douglas JS, Morris DC, King SB: Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91:979-989, 1995
4. Weintraub WS, Stein B, Kosinski A, Douglas JS, Ghazzal ZM, Jones EL, Morris DC, Guyton RA, Craver JM, King SB: Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 31:10-19, 1998
5. Detre KM, Guo P, Holubkov R, Califf RM, Sopko G, Bach R, Brooks MM, Bourassa MG, Shemin RJ, Rosen AD, Krone RJ, Frye RL, Feit F: Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 99:633-640, 1999
6. Kuntz RE: Importance of considering atherosclerosis progression when choosing a revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma. Circulation 99:847-851, 1999
7. Herlitz J, Wognsen GB, Emanuelsson H, Haglid M, Karlson BW, Karlsson T, Albertsson P, Westberg S: Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care 19:698-703, 1996
8. Barsness GW, Peterson ED, Ohman EM, Nelson CL, DeLong ER, Reves JG, Smith PK, Anderson RD, Jones RH, Mark DB, Califf RM: Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 96:2551-2556, 1997
9. The BARI Investigators: Influence of diabetes on 5-year mortality in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation 96:1761-1769, 1997
10. The BARI Investigators: Comparison of coronary artery bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 335:217-225, 1996
11. Bowman BH, Kurosky A: Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet 12:189-261, 1982
12. Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, Levy AP: Structure-function analysis of the antioxidant properties of haptoglobin. Blood 98:3693-3698, 2001
13. Levy AP, Roguin A, Marsh S, Nakhoul FM, Herer P, Hochberg I, Skorecki K: Haptoglobin phenotype and vascular complications in diabetes. N Engl J Med 343:369-370, 2000
14. Nakhoul F, Marsh S, Hochberg I, Leibu R, Miller BP, Levy AP: Haptoglobin phenotype and diabetic retinopathy. JAMA 284:1244-1245, 2000
15. Nakhoul FM, Zoabi R, Kanter Y, Zoabi M, Skorecki K, Hochberg I, Leibu R, Miller B, Levy AP: Haptoglobin phenotype and diabetic nephropathy. Diabetologia 44:602-604, 2001
16. Howard BV, Lee ET, Cowan LD, Devereux RB, Galloway JM, Go OT, Howard WJ, Rhoades ER, Robbins DC, Sievers ML, Welty TK: Rising tide of cardiovascular disease in American Indians: the Strong Heart Study. Circulation 99:2389-2395, 1999
17. Levy AP, Hochberg I, Jablonksi K, Resnick HE, Lee ET, Best L, Howard BV: Haptoglobin phenotype is an independent predictor for cardiovascular disease in individuals with diabetes: the Strong Heart Study. J Am Coll Cardiol 40:1984-1990, 2002
18. Koch W, Kastrati A, Mehilli J, Bottiger C, von Beckerath N, Schomig A: Insertion/deletion polymorphism of the angiotensin 1 converting enzyme gene is not associated with restenosis after coronary stent placement. Circulation 102:197-202, 2000
19. Kastrati A, Schomig A, Seyfarth N, Koch W, Elezi S, Bottiger C, Mehilli J: PI polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 99:1005-1010, 1999
20. Bottiger C, Kastrati A, Koch W, Mehilli J, von Beckerath N, Dirschinger J, Gawaz M, Schomig A: Polymorphism of platelet glycoprotein IIb and risk of thrombosis and restenosis after coronary stent placement. Am J Cardiol 84:987-991, 1999
21. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schomig A, Kastrati A: Genotyping of common haptoglobin polymorphism Hp based on the polymerase chain reaction. Clin Chem 48:1377-1382, 2002
22. Roguin A, Ribichini F, Ferrero V, Matullo G, Herer P, Wijns W, Levy AP: Haptoglobin phenotype and the risk of restenosis after coronary artery stent implantation. Am J Cardiol 89:806-810, 2002
23. Roguin A, Hochberg I, Nikolsky E, Markiewicz W, Meisel SR, Hir J, Grenadier E, Beyar R, Levy AP: Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 87:330-332, 2001
24. Suleiman M, Kapeliovich MR, Roguin A, Aronson D, Meisel SR, Shochat M, Reisner SA, Hammerman H, Lotan R, Levy NS, Levy AP: Haptoglobin type and 30-day mortality in diabetic individuals presenting with myocardial infarction (Letter). Diabetes Care 26:2699, 2003
25. Hochberg I, Roguin A, Nikolsky E, Chanderaskekhar PV, Cohen S, Levy AP: Haptoglobin phenotype and coronary artery collaterals in diabetic patients. Atherosclerosis 161:441-446, 2002
26. Sabri M, DiSciascio G, Cowley M, Alpert D, Vetrovec G: Collateral recruitment: functional significance and relationship to rate of vessel closure. Am Heart J 121:876-880, 1991
27. Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, Levy AP: Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 92:1193-1200, 2003